Related search

Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Annals of Hematology
MedicineHematology
2014English

Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Nivolumab for Relapsed/Refractory Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure – Polish Lymphoma Research Group Real-Life Experience

Acta Haematologica Polonica
OncologyHematology
2018English

Pet-Adapted Nivolumab +/- Ice as Initial Salvage Therapy in Relapsed/Refractory Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

PD-1 Blockade With Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

New England Journal of Medicine
Medicine
2015English

Major Clinical Response to Nivolumab in Relapsed/Refractory Hodgkin Lymphoma After Allogeneic Stem Cell Transplantation

Bone Marrow Transplantation
TransplantationHematology
2016English

Brentuximab Vedotin for Relapsed or Refractory CD30+ Hodgkin Lymphoma: A Multicenter Analysis From Asia

OncoTargets and Therapy
OncologyPharmacology
2014English

Pulmonary Toxicity in Paediatric Patients With Relapsed or Refractory Hodgkin Lymphoma Receiving Brentuximab Vedotin

British Journal of Haematology
Hematology
2018English

Brentuximab Vedotin and Bendamustine as Salvage Therapy for Primary Refractory or Relapsed Hodgkin Lymphoma: A Multicentre Experience of the Polish Lymphoma Research Group

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy